Cello Health plc (CLL.L) (CLL) Share Price, News & Analysis

Company Overview

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment provides market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 453,244 shs
• Market Capitalization: £178.84 million
• P/E Ratio: N/A
• Dividend Yield: 1.34%
• Price Target: N/A
• Consensus Rating: N/A

CLL Stock Analysis - Frequently Asked Questions

How do I buy shares of Cello Health plc (CLL.L)?

Shares of CLL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Cello Health plc (CLL.L) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cello Health plc (CLL.L) investors own include Lloyds Banking Group (LLOY), Saga (SAGA), QinetiQ Group (QQ), Modern Water plc (MWG.L) (MWG) and IGas Energy (IGAS).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Business Services
• Industry: Marketing Services
• Sub-Industry: N/A
• Current Symbol: LON:CLL
• CIK: N/A
• Web: www.cellogroup.com
• Phone: +44-20-78128460
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 14.72
• Current Ratio: 1.15
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: £166.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 20.13
• Book Value: GBX 77.60 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 111,080,000
• Free Float: N/A
• Market Cap: £178.84 million
• Optionable: Not Optionable
• Beta: N/A